Lectin-functionalized mesoporous silica nanoparticles for endoscopic detection of premalignant colonic lesions

Chen, Nai-Tzu; Souris, Jeffrey S.; Cheng, Shih-Hsun; Chu, Chia-Hui; Wang, Yuchao; Konda, Vani J.; Dougherty, Urszula; Bissonnette, Marc; Mou, Chung‐Yuan; Chen, Chin-Tu; Lo, Leu‐Wei

doi:10.1016/j.nano.2017.03.014

Cited by 37 publications

(22 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Generally, if drug diffusion across the polymeric matrix is faster than matrix degradation, then the mechanism of drug release is driven mainly by diffusion, otherwise, polymer degradation is the limiting step in drug release. Consequently, drug release normally follows first- (via matrix degradation) rather than zero-order (via diffusion) kinetics [42] . Particle size also strongly influences drug release through mediating both diffusion and matrix degradation.…”

Section: Designing Nanomedicines For Nonparental Administrationmentioning

confidence: 99%

Challenges in nonparenteral nanomedicine therapy

Praveen

Kalarikkal

Thomas

2021

Theory and Applications of Nonparenteral Nanomedicines

View full text Add to dashboard Cite

Section: Designing Nanomedicines For Nonparental Administrationmentioning

confidence: 99%

Challenges in nonparenteral nanomedicine therapy

Praveen

Kalarikkal

Thomas

2021

Theory and Applications of Nonparenteral Nanomedicines

View full text Add to dashboard Cite

“…Moreover, the C-type lectin receptor is also expressed exclusively by macrophages and exploited for cancer treatment. Lectin-functionalized MSN have recently been experimented in a mouse colon cancer model [ 123 ].…”

Section: Surface Modification Of Msn For Passive and Active Targetmentioning

confidence: 99%

Multimodal Decorations of Mesoporous Silica Nanoparticles for Improved Cancer Therapy

Barui

Cauda

2020

Pharmaceutics

View full text Add to dashboard Cite

The presence of leaky vasculature and the lack of lymphatic drainage of small structures by the solid tumors formulate nanoparticles as promising delivery vehicles in cancer therapy. In particular, among various nanoparticles, the mesoporous silica nanoparticles (MSN) exhibit numerous outstanding features, including mechanical thermal and chemical stability, huge surface area and ordered porous interior to store different anti-cancer therapeutics with high loading capacity and tunable release mechanisms. Furthermore, one can easily decorate the surface of MSN by attaching ligands for active targeting specifically to the cancer region exploiting overexpressed receptors. The controlled release of drugs to the disease site without any leakage to healthy tissues can be achieved by employing environment responsive gatekeepers for the end-capping of MSN. To achieve precise cancer chemotherapy, the most desired delivery system should possess high loading efficiency, site-specificity and capacity of controlled release. In this review we will focus on multimodal decorations of MSN, which is the most demanding ongoing approach related to MSN application in cancer therapy. Herein, we will report about the recently tried efforts for multimodal modifications of MSN, exploiting both the active targeting and stimuli responsive behavior simultaneously, along with individual targeted delivery and stimuli responsive cancer therapy using MSN.

show abstract

“…Furthermore, Chen and colleagues exploited the fucose-binding lectin UEA1 for colorectal adenocarcinoma, adenoma and polyposis coli targeting and detection. Fluorescently labeled and UEA1 carrying MSN were successfully tested in a mouse colon cancer model as a contrast agent to visualize malignant lesions in the colon [ 50 ].…”

Section: Modifications To Control Cellular Uptake Drug Release Anmentioning

confidence: 99%

Mesoporous Silica Nanoparticles as Drug Delivery Vehicles in Cancer

2017

View full text Add to dashboard Cite

Even though cancer treatment has improved over the recent decades, still more specific and effective treatment concepts are mandatory. Surgical removal is not always possible, metastases are challenging and chemo- and radiotherapy can not only have severe side-effects but also resistances may occur. To cope with these challenges more efficient therapies with fewer side-effects are required. One promising approach is the use of drug delivery vehicles. Here, mesoporous silica nanoparticles (MSN) are discussed as biodegradable drug carrier to improve efficacy and reduce side-effects. MSN excellently fulfill the criteria for nanoparticulate carriers: their distinct structure allows high loading capacity and a plethora of surface modifications. MSN synthesis permits fine-tuning of particle and pore sizes. Moreover, drug release can be tailored through various gatekeeper systems which are for example pH-sensitive or redox-sensitive. Furthermore, MSN can either enter tumors passively by the enhanced permeability and retention effect or can be actively targeted by various ligands. PEGylation prolongs circulation time and availability. A huge advantage of MSN is their explicitly low toxic profile in vivo. Yet, clinical translation remains challenging. Overall, mesoporous silica nanoparticles are a promising tool for innovative, more efficient and safer cancer therapies.

show abstract

Lectin-functionalized mesoporous silica nanoparticles for endoscopic detection of premalignant colonic lesions

Cited by 37 publications

References 48 publications

Challenges in nonparenteral nanomedicine therapy

Challenges in nonparenteral nanomedicine therapy

Multimodal Decorations of Mesoporous Silica Nanoparticles for Improved Cancer Therapy

Mesoporous Silica Nanoparticles as Drug Delivery Vehicles in Cancer

Contact Info

Product

Resources

About